GB5121

GB5121 is an orally available, highly selective, irreversible, covalent small molecule inhibitor of Bruton's tyrosine kinase (BTK). It was specifically designed to address the limitations of existing BTK inhibitors by providing improved selectivity and central nervous system (CNS) penetration. Upon oral administration, GB5121 selectively and irreversibly binds to BTK, inhibiting its activity and thereby blocking B-cell receptor signaling pathways. This results in the prevention of B-cell activation and downstream survival signaling. Preclinical studies demonstrated that GB5121 achieves rapid equilibrium into the brain with high CNS target occupancy and a favorable brain-to-plasma ratio compared to other BTK inhibitors. The drug was developed for hematologic malignancies with CNS involvement, particularly primary central nervous system lymphoma[1][2][3][4][5]. However, development was discontinued following serious adverse events observed in clinical trials[6][7].